Keytruda's High Price Puts Revolutionary Cancer Drug Out of Reach for Most in Costa Rica

Keytruda (pembrolizumab) has been hailed as a revolutionary treatment for various cancers, offering new hope to patients. However, in Costa Rica, the reality for many is a frustrating and protracted struggle to access this life-saving medication. Patients have endured months of navigating complex bureaucratic processes, facing committee rejections, filing appeals, and even resorting to legal orders, only to find their access to Keytruda still uncertain.

This situation highlights a critical disconnect between medical advancement and equitable access. While the drug's efficacy is not in doubt, market barriers and systemic inefficiencies in Costa Rica are creating significant hurdles for those who need it most. The delays and legal battles underscore the urgent need for a more streamlined and accessible healthcare system that prioritizes patient well-being over bureaucratic red tape.

The prolonged wait times and the need for legal recourse are not just inconveniences; they represent precious time lost in the fight against cancer. This raises serious questions about the healthcare system's ability to deliver on its promise of providing timely and effective treatment to all citizens. The case of Keytruda in Costa Rica serves as a stark reminder that even the most promising medical breakthroughs can be rendered inaccessible by systemic failures.

“

Patients with advanced cancer in Costa Rica have waited months between committees, rejections, appeals, and unfulfilled court orders for this medication.